Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Missing Deadline, In Discussions With Quest On Potential Dx Deal

NEW YORK, July 1 (GenomeWeb News) - Missing its self-imposed deadline to announce a diagnostics collaboration, Ciphergen Biosystems today said it is "in discussions" with Quest Diagnostics about a potential diagnostic alliance.

 

The company had promised to announce a "pivotal" diagnostics alliance before the end of June.

 

In a terse SEC filing today, the company said "the nature of the potential alliance, including the financial and business terms, have not yet been agreed to and there can be no assurance that an alliance will be completed between the two parties."

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.